<DOC>
	<DOC>NCT00687609</DOC>
	<brief_summary>The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.</brief_summary>
	<brief_title>Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE</brief_title>
	<detailed_description>In the past adolescents with cannabis abuse have been excluded from studies in which atomoxetine for ADHD symptoms was studied. In this study the efficacy of atomoxetine on symptoms of ADHD in adolescents with ADHD and comorbid cannabis abuse will be studied.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Diagnosis ADHD based on the Diagnostic and Statistical Manual of Mental Disorders (DSMIVTR) At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating ScaleIVParent Version Cannabis Abuse or dependence based on the DSMIVTR, and using a minimum of 5 joints per week Weight under 20 kilograms (kg) Patients at serious suicidal risk Patients with alcohol or drug abuse (other than cannabis) Patients who in the investigator's judgement are likely to need psychotropic medication + psychotherapy apart from atomoxetine</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder with Cannabis Abuse</keyword>
	<keyword>Marihuana Abuse</keyword>
	<keyword>Comorbid Cannabis Abuse</keyword>
</DOC>